RT Journal Article
SR Electronic
T1 Time is of the essence: impact of delays on effectiveness of contact tracing for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.09.20096289
DO 10.1101/2020.05.09.20096289
A1 Mirjam Kretzschmar
A1 Ganna Rozhnova
A1 Martin Bootsma
A1 Michiel van Boven
A1 Janneke van de Wijgert
A1 Marc Bonten
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.09.20096289.abstract
AB Background With confirmed cases of COVID-19 declining in many countries, lockdown measures are gradually being lifted. However, even if most social distancing measures are continued, other public health measures will be needed to control the epidemic. Contact tracing either via conventional methods or via mobile app technology is central to control strategies during de-escalation of social distancing. It is therefore essential to identify key factors for a contact tracing strategy (CTS) to be successful.Methods We evaluated the impact of timeliness and completeness in various steps of a CTS using a stochastic mathematical model with explicit time delays between time of infection, symptom onset, diagnosis by testing, and isolation. The model also includes tracing of close contacts (e.g. household members) and casual contacts with different delays and coverages. We computed effective reproduction numbers of a CTS (Rcts) for a population with social distancing measures and various scenarios for isolation of index cases and tracing and quarantine of its contacts.Findings In the best-case scenario (testing and tracing delays of 0 days and tracing coverage of 100%) the effective reproduction number will be reduced with 50% from 1.2 (with social distancing only) to 0.6 (Rcts) by contact tracing. A testing delay of 3 days requires tracing delay or coverage to be at most 1 day or at least 80% to keep Rcts below 1, with the Rcts reduction being 15% and 17%, respectively. With a testing delay of 4 days, even the most efficient CTS cannot reach Rcts values below 1. The effect of minimizing tracing delay (e.g., with app-based technology) declines with declining coverage of app use, but app-based tracing remains more effective than conventional contact tracing even with 20% coverage. The proportion of transmissions per index case that can be prevented depending on testing and tracing delay and isolation of index cases ranges from above 80% in the best-case scenario (testing and tracing delays of 0 days) to 40% and 17% with testing delays of 3 and 5 days, respectively.Interpretation Minimizing testing delay is of key importance for the effectiveness of CTS. Optimizing testing and tracing coverage and minimizing tracing delays, for instance with app-based technology further enhances effectiveness of CTS, with a potential to prevent up to 80% of all transmissions. The process of conventional contact tracing should be reviewed and streamlined, while mobile app technology may offer a tool for gaining speed in the process.Evidence before this study As of 8 May 2020, the novel coronavirus (SARS-CoV-2) has spread globally and has caused more than 263,000 confirmed deaths of COVID-19 worldwide. In the absence of effective medicines and vaccines, many countries have implemented strict measures of social distancing, thereby reducing transmission and bringing the epidemic under control. For lifting these measures, adequate tools are needed to deal with possible newly arising transmission clusters. Strategies including isolation of confirmed and suspected cases, and identification and quarantining of their contacts are considered a key part of the response during de-escalation of social distancing. As a substantial portion of transmission may occur before the onset of symptoms and before cases can be isolated, it is unclear how successful contact tracing strategies (CTS) can be in reducing onward transmission.Added value of this study We performed a systematic analysis of the various steps required in the process of testing and diagnosing an index case as well as tracing and isolation possible secondary cases of the index case. We then used a stochastic transmission model which makes a distinction between close contacts (e.g. household members) and casual contacts to assess which steps and (possible) delays are crucial in determining the effectiveness of CTS. We evaluated how delays and the level of contact tracing coverage influence the effective reproduction number, and how fast CTS needs to be to keep the reproduction number below 1. We also analyzed what proportion of onward transmission can be prevented for short delays and high contact tracing coverage. Assuming that around 40% of transmission occurs before symptom onset, we found that keeping the time between symptom onset and isolation of an index case short (<3 days) is imperative for a successful CTS. This implies that the process leading from symptom onset to receiving a positive test should be minimized by providing sufficient and easily accessible testing facilities. In addition, reducing contact-tracing delays also helps to keep the reproduction number below 1.Implications of all the available evidence Our analyses highlight that CTS will only contribute to containment of COVID-19 if it can be organised in a way that time delays in the process from symptom onset to isolation of the index case and his/her contacts are very short. The process of conventional contact tracing should be reviewed and streamlined, while mobile app technology may offer a tool for gaining speed in the process.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was partly funded by ZonMw project number 91216062Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data were used for this study.